OUTPACE Trademark

Trademark Overview


On Friday, January 17, 2025, a trademark application was filed for OUTPACE with the United States Patent and Trademark Office. The USPTO has given the OUTPACE trademark a serial number of 99007063. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, January 17, 2025. This trademark is owned by Outpace Bio, Inc.. The OUTPACE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery and development; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; protein engineering and design services; cell programming services; research, development, discovery and consulting services in the fields of cell therapy and immuno-oncology; research, development, engineering and testing services in the fields of therapeutics, ce...
outpace

General Information


Serial Number99007063
Word MarkOUTPACE
Filing DateFriday, January 17, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, January 17, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDrug discovery and development; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; protein engineering and design services; cell programming services; research, development, discovery and consulting services in the fields of cell therapy and immuno-oncology; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical and clinical research and development services; scientific research and development, scientific laboratory services, medical and scientific research, biotechnology research and synthetic biology research, all of the foregoing relating to human beings; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; development of pharmaceutical preparations and drugs in the field of gene therapy; medical research laboratory services, namely, tissue material processing and analysis in the field of cell therapy and immuno-oncology; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others; providing a website featuring information in the scientific, medical, biotechnology, biomedical, and pharmaceutical fields; provision of drug discovery, development and testing information; providing a website featuring information in the field of drug discovery, development and testing; provision of information in the field of prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; providing a website featuring information in the field of prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; provision of information in the field of cell therapy and immuno-oncology; providing a website featuring information in the field of cell therapy and immuno-oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing a website featuring information in the field of pharmaceuticals and clinical trials; provision of scientific, medical, biotechnology, biomedical, and pharmaceutical information; providing information relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of human diseases, disorders and conditions;

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 17, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOutpace Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Trademark Events


Event DateEvent Description
Friday, January 17, 2025NEW APPLICATION ENTERED
Friday, January 17, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED